Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

U.K. preps COVID-19 booster program

By Brian Buntz | July 1, 2021

vaccine

Photo by Frank Meriño from Pexels

The U.K. is laying the groundwork for a COVID-19 vaccine booster program starting in the fall, making it one of the first nations to do so.

The interim initiative would prioritize providing boosters to those 70 and older, other high-risk patients and frontline health workers starting in September.

Officials at the Joint Committee on Vaccination and Immunisation (JCVI) also are considering administering COVID-19 vaccines in tandem with flu vaccines. The organization doesn’t anticipate that variant-specific vaccines will be available in time for the launch of the new vaccination drive.

A second phase of the vaccine campaign would provide shots for those 50 and older, adults between the ages of 16 and 49 years who are in an at-risk group and adult household contacts of immunosuppressed individuals.

JCVI officials, however, haven’t made definitive plans yet and stated that the proposals regarding COVID-19 vaccine boosters are precautionary.

U.S. officials have discussed the possibility of supporting vaccine booster initiatives later this year but have stopped short of predicting they would be necessary.

U.K. has vaccinated more of its citizens than the U.S. Some 85% of U.K. adults have received at least one dose, and more than 60% are fully immunized. By contrast, 63.6% of the U.S. population aged 12 and up have received at least one dose. A total of 54.6% are fully vaccinated.

A handful of studies suggest that immunity from COVID-19 vaccines lasts at least six months. Immunity may last for a couple of years for healthy individuals.

As more data become available, the JCVI may update its proposals. “We will continue to review emerging scientific data over the next few months, including data relating to the duration of immunity from the current vaccines. Our final advice on booster vaccination may change substantially,” said Professor Wei Shen Lim, COVID-19 Chair for JCVI, in a statement.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Pfizer logo
Pfizer and BioNTech seek EMA authorization for COVID-19 vaccination in young children
Pfizer logo
FDA allows pharmacists to prescribe Paxlovid 
vaccine
Will COVID-19 vaccines be updated by fall? 
COVID-19 vaccine
Young children in U.S. now eligible for COVID-19 vaccination

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards